An international clinical trial with three-year follow-up, the results of which have been published in JAMA Dermatology, provides new evidence on the long-term outcomes of patients with moderate to severe plaque psoriasis treated with bimekizumab. Dr. Anna López-Ferrer, a researcher in the Dermatology group at Institut de Recerca Sant Pau (IR Sant Pau) and a member of the Dermatology Department at Hospital de Sant Pau, is listed as a co-author of this analysis, which specifically focuses on patient-reported outcomes.
Psoriasis is a chronic immune-mediated inflammatory disease that can have a significant impact on quality of life. Beyond visible skin lesions, symptoms such as itching, pain, and scaling directly affect physical, emotional, and social well-being. In this context, the incorporation of patient-centered measures in clinical trials has become a key element in comprehensively assessing therapeutic benefit.
The BE RADIANT study is an international multicenter phase 3b trial that included an open-label extension through three years of follow-up. The published analysis evaluates so-called patient-reported outcomes (PROs), that is, outcomes reported directly by patients using validated instruments that measure symptoms and health-related quality of life.
The data show that the improvements observed during the initial phases of treatment were sustained over time. In particular, persistent reductions were recorded in symptoms such as itching and pain, along with meaningful improvements in dermatology-specific quality-of-life questionnaires. This information is especially relevant in a chronic condition requiring long-term treatment, in which the patient’s perception constitutes an essential component of therapeutic evaluation.
“Having three-year data that include patient-centered measures is particularly relevant in a chronic disease such as psoriasis. These results allow us to assess not only clinical response but also the real impact of treatment on patients’ quality of life over the long term,” says Dr. Anna López-Ferrer.
Publication in a leading international journal such as JAMA Dermatology underscores the scientific relevance of the trial and the importance of integrating clinical variables and patient-reported outcomes into the design of long-term studies. For IR Sant Pau, this type of research helps strengthen clinical research in inflammatory diseases and supports progress toward a more comprehensive, patient-experience-centered therapeutic evaluation.
Participation in international multicenter studies consolidates the team’s expertise in clinical trials and in the rigorous evaluation of new therapeutic strategies in psoriasis, in line with IR Sant Pau’s commitment to high-quality clinical research.
Reference Article:
Augustin M, Feldman SR, Warren RB, Armstrong A, Vender R, López-Ferrer A, Dawe WH, Lambert J, Szilagyi B, Hoepken B, Warham R, Gottlieb AB. Three-year Patient-reported Outcomes from bimekizumab for plaque psoriasis: The BE RADIANT randomized clinical trial with open-label extension. JAMA Dermatol. 2026. https://doi.org/10.1001/jamadermatol.2025.6055
